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Development of post-transcriptional gene silencing (PTGS) agents for therapeutic purposes is an immense challenge in modern biol-
ogy. Established technologies used to knockdown a speciﬁc target RNA and its cognate protein: antisense, ribozyme, RNAi, all condi-
tionally depend upon an initial, critical annealing event of the PTGS ligand to a target RNA. In this review we address the nature of the
bottlenecks, emphasizing the biocomplexity of target RNA structure, that currently limit PTGS therapeutic development. We brieﬂy
review existing and emerging technologies designed to release these constraints to realize the potential of PTGS agents in gene based
therapies.
 2007 Elsevier Ltd. All rights reserved.
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problem. Target mRNA is folded into secondary and ter-
tiary structure, is coated with heterogeneous proteins,
undergoes dynamic ﬂuctuations in structure, and resides
in intracellular compartments with diﬀerent lifetimes
(nucleus, cytoplasm, ribosomes, etc.). These factors
severely constrain the locations in the RNA target that
are accessible, and the range of timescales and spatial envi-
ronments available for small PTGS ligand attack. It is nec-
essary to identify stable, accessible regions for PTGS
within this cellular milieu. Moreover, the PTGS ligand
must present in the same locale as the target, at suﬃcient
concentrations to allow diﬀusion-limited interaction, and
in conformational state(s) that enable eﬀective annealing
and catalysis to achieve successful knockdown. These chal-
lenges deﬁne the slow entry of PTGS agents into the phar-
maceutical market, despite their obvious clinical potential.
In fact, only a single antisense agent, Vitrovene (fomiver-
sen) (Novartis, Isis), was approved in August 1998 by the
FDA for ocular use in CMV retinitis. Vitrovene (Isis-
2922) is a 21-mer phosphorothioate antisense molecule that
anneals to the coding region of the immediate early (IE55
gene) mRNA transcribed from the CMV genome (Ander-
son, Fox, Brown-Driver, Martin, & Azad, 1996). No ribo-
zyme or RNAi agents are yet approved but, like antisense
agents, many are in clinical trials. The therapeutic potential
of PTGS agents motivates the development of high
throughput screening (HTS) approaches to embrace the
biocomplexity challenges presented by the target and the
ligand. In this paper, we present aspects of target RNA
biology that will convince the reader about the complexity
of PTGS development. We then present the bottlenecks
that exist in PTGS development and an overview of tech-
nologies that are emerging to deconstrain these bottle-
necks. The goal is more rapid realization of eﬃcacious
and safe PTGS therapeutics for the eye or other organs.
Given the complexity of the challenge of developing
RNA-directed drugs it is not at all surprising that there
has been slow entry into the pharmaceutical marker. It
costs hundreds of millions of dollars to take a drug to clin-
ical market. RNA-directed drugs are still largely on the
horizon. Recent emergence of tools to address diﬃcult sci-
entiﬁc issues underlying the biocomplexity of the transcri-
ptosome and RNA structure/function oﬀer substantial
hope that the dawn of RNA-directed drugs is visible in
the near future.
2. PTGS technologies
All PTGS technologies depend upon annealing between
target RNA and the AS component of the PTGS ligand.
AS agents are commonly built upon a deoxyribonucleic
acid backbone, are transfected into cells, and are designed
to bind to an accessible region of the target RNA, to pro-
mote RNaseH mediated cleavage of target and/or transla-
tional inhibit through ribosome stalling. Therefore, AS
agents must recognize an accessible region and bind tightlyin order to insure a long hybrid lifetime. Ribozyme agents
are commonly expressed as RNA molecules from genetic
templates or delivered as synthetic ribonucleotides with
ribose base modiﬁcations to increase stability. Rzs must
bind to an accessible region of target RNA, cleave the tar-
get RNA, and then dissociate from the target and perform
the same series of reactions (enzymatic turnover) with
other substrate RNA molecules. Rzs must bind to target
RNA with suﬃcient strength to insure a hybrid lifetime
that allows chemical cleavage of target RNA, but not so
strongly that the product dissociation is slow and inhibits
turnover (product inhibition). RNAi agents are commonly
expressed as short hairpin RNAs (shRNA), or delivered as
chemically stabilized short interfering RNAs (siRNAs).
Expressed shRNAs are cleaved in the nucleus by Drosha
endonuclease and further processed by the cytoplasmic
nuclease Dicer III, to achieve a mature RNAi. The double
stranded RNAi is recognized by the RNA-induced silenc-
ing complex (RISC), which selects the AS strand on the
basis of designed thermodynamic end stability, and then
uses this charged RISC to anneal to accessible regions of
target RNAs to promote target cleavage. The RISC com-
plex is tolerant of several mutations in the 14 nt long AS
stretch that allows target recognition. In addition siRNAs
can simulate microRNAs and bind to the 3 0 untranslated
region of mRNAs to inhibit translation. These factors are
likely responsible for the plethora of oﬀ-target eﬀects of
RNAi and related toxicity (Fedorov et al., 2006).
3. Bottlenecks in development of PTGS therapies
There are several phases and bottlenecks in the develop-
ment of PTGS agents: (1) identiﬁcation of candidate
molecular targets, (2) validation of targets, (3) identifying
accessible regions in target RNAs, (4) identifying lead can-
didate PTGS agents targeting those accessible regions, (5)
optimizing lead candidates, (6) preclinical testing in appro-
priate animal models. Each of these steps embraces bio-
complexity that delays the speed at which PTGS agents
are developed. We recently reported (Sullivan, Yau, Tag-
gart, Butler, & Kolniak, 2007, Elsevier Conference, Retinal
Degeneration and Gene Therapy) that several of these bot-
tlenecks can be relieved with technologies emerging, in
part, from work this laboratory.
3.1. Validation of molecular targets for PTGS therapy
Validation of an ideal molecular target is the establish-
ment of knowledge that chronic upregulation of a normal
wild type (WT) target RNA and protein, or expression of
a mutant target RNA and protein, is necessary and suﬃ-
cient for the emergence of disease. Other molecules may
be essential for disease to emerge and so a validated target
may be necessary but not suﬃcient for disease. It is critical
to understand that the disease emerges in time in a cellular
system of gene expression. The emerging ﬁeld of systems
biology addresses these issues.
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rationale to look to the mutant mRNA and protein as nec-
essary and suﬃcient to initiate the disease process, but
there are additional considerations. First, there is tremen-
dous allelic and phenotypic heterogeneity in genetic retinal
degenerations. Mutations in a single gene can cause multi-
ple clinical anatomic phenotypes or a range of phenotypes
within a single clinical disease classiﬁcation. Consider auto-
somal dominant mutations in peripherin/RDS which cause
several clinically distinct syndromes: retinitis pigmentosa
(RP), macular dystrophy, pattern dystrophy, fundus ﬂav-
imaculatus and retinitis pigmentata albescens (Kajiwara
et al., 1991; Kajiwara, Sandberg, Berson, & Dryja, 1993;
Nichols, Sheﬃeld, Vandenburgh, Drack, et al., 1993; Tra-
vis & Hepler, 1993; Weleber, Carr, Murphey, Sheﬃeld, &
Stone, 1993; Wells, Wroblewski, Keen, Inglehearn, et al.,
1993). Mutations in rod opsin can cause retinitis pigmen-
tosa, congenital stationary night blindness, or retinitis
punctata albescens (see Daiger, Sullivan, Bowne, & Rossit-
er, 2007). Phenotypic heterogeneity is ultimately a problem
at the protein level of systems biology, as diﬀerent muta-
tions in even a single amino acid codon can lead to starkly
diﬀerent clinical diseases. Diﬀerent mutations in a single
gene can cause retinal degenerations with a broad range
of times of onset and rates of loss. For example, autosomal
dominant mutations in rod opsin can cause a broad range
of phenotypes including early onset and rapidly progressive
RP (e.g. C187Y), later onset and slowly progressive RP
(e.g. P23H), or congenital stationary night blindness (e.g.
G90D). How variation in the structural and molecular
biology of such proteins contributes to the broad time
scales of disease is far from understood, even for proteins
such as rod rhodopsin that are well characterized.
Second, to develop PTGS therapeutics a ﬁrst critical
step is to determine whether a given mutation or set of
mutations causes haploinsuﬃciency, gain-of-function, or
dominant negative eﬀects. A dominant mutation may cause
loss of functional protein and the 50% of WT protein
expressed from the remaining unmutated allele may be
insuﬃcient to promote cell function and vitality. Alterna-
tively, the mutated allele may express proteins that have
direct toxic eﬀects on cell metabolism. Mutant proteins
may misfold and become trapped in the endoplasmic retic-
ulum and Golgi apparatus, where they can elicit the
unfolded protein response that can lead to apoptosis
(Illing, Rajan, Bence, & Kopito, 2002; Johnston, Ward,
& Kopito, 1998; Kopito, 2000; Lai, Teodoro, & Volchuk,
2007; Rajan, Illing, Bence, & Kopito, 2001; Ron & Walter,
2007; Saliba, Munro, Luthert, & Cheetham, 2002). Mutant
proteins may traﬃc inappropriately and cause toxicity in
the new cellular locales in which they take residence.
Mutant proteins may have aberrant signaling properties
or build aberrant macromolecular structures that create
toxicity for the cell. A mutant protein could interact with
a plethora of potential signaling and regulation pathways,
each of which has unique input/output properties and
dynamic range. Another gain-of-function eﬀect of a mutantprotein is called the dominant negative eﬀect where a
mutant protein acts to prevent the normal function of the
WT protein. For example, the mutant protein may prevent
the normal traﬃcking of the WT protein to the region of
the cell where it is otherwise destined. Prior to development
of PTGS agents for autosomal dominant diseases, consid-
eration should be given to the nature of the cellular eﬀects
of the mutation (haploinsuﬃciency, gain-of-function, dom-
inant negative). Therapy chosen should depend upon the
cellular defects identiﬁed. Mutations that create haploin-
suﬃciency (autosomal recessive, dominant negative) would
beneﬁt from WT gene reconstitution rather than attempts
to silence the mutant gene or change the ratio of mutant/
WT mRNAs with PTGS therapy. It is the gain-of-function
mutations that can beneﬁt from PTGS therapies. Most
autosomal dominant mutations are likely to be gain-of-
function mutations. Haploinsuﬃciency impact can be
determined with heterozygous knockout mouse models
for the gene in question and comparing function and cell
viability with WT and knockout mice in both juvenile
and older animals. Many gain-of-function eﬀects can be
determined in cell culture studies, although cell culture
studies are not always reliable (e.g. Sung, Schneider, Agar-
wal, Papermaster, & Nathans, 1991). For example, mutant
human P23H expression in HEK293S cells traps in the
endoplasmic reticulum and Golgi apparatus, whereas
in vivo P23H traﬃcs, at least in part, to the outer segments
(Olsson et al., 1992). Complementary studies to determine
gain-of-function eﬀects should be conducted in transgenic
mouse models. Dominant negative eﬀects can be demon-
strated by overexpression of WT protein and determining
the extent to which it ameliorates the phenotype. However,
it is impractical to develop transgenic models for all muta-
tions in a given mutation-abundant gene, to the extent that
the mouse represents human biology. Correlative studies
involving existing animal models and well chosen cell cul-
ture systems may aid to address this issue.
Several studies have shown the potential for use of Rz or
RNAi PTGS agents for therapy of hereditary retinal
degenerations when the targets are rod opsin or peripherin
(e.g. Cashman, Binkley, & Kumar-Singh, 2005; Kiang
et al., 2005; Lewin et al., 1998; Millington-Ward et al.,
1997; Sullivan, Pietras, Shin, & Misasi, 2002). These and
other studies show that PTGS agents can be eﬃcacious
to slow retinal degenerations in rodent models. Toxicity
studies have not yet been conducted.
The greatest potential clinical beneﬁt of PTGS agents
exists not in autosomal dominant diseases but rather in ret-
inal degenerations due to chronic upregulation or overex-
pression of WT mRNAs/proteins. Age-related macular
degeneration (AMD) is an ideal model for PTGS therapy.
There are validated molecular targets that underlie dry
AMD pathogenesis (Petrukhin, 2007). In wet AMD due
to pathological angiogenesis, anti-vascular endothelial
growth factor (VEGF) therapy has established that VEGF
is a suitable molecular target for PTGS therapy. VEGF is
overexpressed in the emergence of choroidal neovasculari-
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replication and migration. Recent studies have developed
shRNAs that are designed to knockdown VEGF mRNA
and protein (Cashman, Bowman, Christoﬀerson, &
Kumar-Singh, 2006). Ultimately, validation of PTGS
agents as candidate therapies can only be determined in
appropriate animal models of human disease. The target
should be overexpressed in the disease, such as with VEGF
and CNV, and knockdown of the target below normal lev-
els should slow or ablate the disease process. Degenerative
macular and retinal diseases emerge over time in retinal cell
biological systems. A given disease may not be modulated
by PTGS attack on a single target. Multiple targets are
likely to have expression levels that correlate with the tem-
poral emergence and progression of a given disease. Some
targets may be upregulated and some downregulated. Mul-
tiple, validated targets may require simultaneous PTGS
modulation for maximum therapeutic eﬃcacy. Regulation
of PTGS agents will likely be needed, however, to avoid
toxicity and/or potential therapeutic haploinsuﬃciency.
And, termination of the therapy should be planned, shouldFig. 1. RNA secondary structures for human disease targets. (upper left) Rod o
1–1400 nt), (lower left) bestrophin (NM_004183, 1–1400 nt) and (lower right)
determined by MFold. Only the ﬁrst 1400 nt could be folded on version 2.3
(P12 nt) (labeled with an asterisk *) are rare in each target (1 in RHO, 4 in RD
and mostly stable intramolecular secondary structure that is expected to resistthe disease be successfully modulated. These are complex
scientiﬁc and technological issues. Retinal gene therapy is
a cellular systems biology problem.3.2. Identifying accessible regions of target RNAs
Accessible regions in a target mRNA must be identiﬁed
before rational design of a PTGS agent can begin. This is
the most diﬃcult bottleneck in PTGS development of any
kind (Rz, antisense, siRNA) because highly accessible sites
are rare in any mRNA. All PTGS technologies are condi-
tionally dependent upon a rate-limiting second-order
molecular annealing event in vivo. A set of predicted sec-
ondary structures is shown for genetic disease target
mRNAs (rod opsin, peripherin, bestrophin) and an mRNA
involved in hypoxic retinal angiogenesis (HIF-1a) (Fig. 1).
Only the minimal folding energy (MFE) structure is shown
for the ﬁrst 1400 nt of each mRNA. Any mRNA target is
expected to be annealed into dense intramolecular second-
ary structure. Ideal annealing platforms are large singlepsin (NM_000539, 1–1400 nt), (upper right) peripherin (RDS) (M62958.1,
HIF-1a (BC012527, 1–1400 nt). Shown are the MFE secondary structures
of MFold on GCG. Note that large single stranded annealing platforms
S, 3 in BEST-1, 3 in HIF-1a). The bulk of the mRNA is folded into dense
annealing of PTGS agents.
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the target mRNAs analyzed.
There are a variety of rational and combinatorial
approaches to identify accessible sites in RNAs. In a pop-
ular approach, discrete or combinatorial ODN binding is
followed by RNaseH cleavage and RNA primer extension
by reverse transcriptase to locate the cleavage sites (Ho
et al., 1998; Scherr & Rossi, 1998). This approach is slow
and cumbersome, gel-based, and has many pitfalls. The
location of the cleavage site is not precisely known in com-
binatorial searches because RNaseH cleaves in the middle
of the ODN: RNA hybrid region without sequence speciﬁc-
ity. Arrays of ODNs can eﬀectively search for accessibility
sites, but this requires specialized machinery and is far from
high throughput. Discrete ribozymes or combinatorial
ribozyme libraries can be used to cleave RNAs with
RNA extension or RT/PCR with 5 0 tailing used to identify
cleavage sites in procedures that are cumbersome and slow
(Lieber & Strauss, 1995). Recent studies from the Clawson
lab have applied in vitro Systematic Evolution of Ligands
by Exponential Enrichment (SELEX) to the challenge of
identifying highly eﬃcient hammerhead ribozyme (hhRz)5' NNNNNNNNNUC NNNNNN 3'    
3' NNNNNNNNNA    NNNNNN 5'
                                   C
        A          U
                                       G
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Fig. 2. SELEX procedure to identify regions of a target mRNA that are acce
from partially overlapping single stranded oligonucleotides and contains a rand
sites). The cDNA library and T7 RNA polymerase are used to transcribe a c
library is designed to anneal to accessible sites that also contain NUC# cleavage
The RNA guide library is then mixed with the target RNA and allowed to ann
the target RNA on nondenaturing gels. Reverse transcription is used to regene
amplify a highly enriches subset of the library that contains sequences capable o
library is then used to reprobe the target and the evolutionary procedure repe
Finally, PCR products are TA cloned and sequenced to identify the accessiblesites in long natively-structured RNA targets (Pan, Devlin,
Kelley, Isom, & Clawson, 2001) (Fig. 2). These approaches
led to hhRzs with catalytic eﬃciencies (kcat/Km) on the
order of 106 M1 min1, comparable to rates observed
against tiny unstructured model RNA targets. This shows
that truly accessible sites can be identiﬁed. This approach
can be conducted in cellular extracts where an RNA target
is made more complex by heterogeneous protein coating.
Combinatorial HTS tools such as SELEX that embrace
molecular evolution are needed to better learn the rules
of selecting regions from the folded RNA that can prove
eﬃcacious for knockdown. We are developing a SELEX
system in HEK293 cells to evolve eﬃcacious hhRzs (Butler,
Misasi, and Sullivan, work in progress).
Over the last 2 years we have completed development of
three complimentary approaches that allow us to rapidly
identify regions of accessibility in target mRNAs for devel-
opment of hhRz or shRNA PTGS agents. Computational
approaches are improving and have been eﬀective to predict
accessible sites in RNAs for PTGS agent development
(Amarzguioui et al., 2000; Ding, Chan, & Lawrence,
2004; Mathews, 2006; Mathews, Burkard, Freier, Wyatt, &NNNNNUC NNNNNN 3'    Target RNA 
NNNNNAG NNNNNN 5'     hhRz Guide RNA
egion 3'
egion....NNNNNNCTNNNNNNNNN.Constant Region.. RES 5'
3'.. Constant Region.. RES 5'
PCR
egion....NNNNNNGANNNNNNNNN.Constant Region..RES 3'
egion....NNNNNNCTNNNNNNNNN. Constant Region..RES 5'
In Vitro Transcription (T7 RNA Pol)
Region....NNNNNNGANNNNNNNNN.Constant Region..RES 3'
Single Stranded DNA Library
Double Stranded DNA Library
A
    Guide RNA Library 
Guide RNA: Target RNA Complex
Folded Target RNA
(purified by non-denaturing gel electrophoresis)
B
tion
g
Transcription
A        B       C        D 
ONE ROUND OF EVOLUTION
ssible for hhRz design. A double stranded cDNA library is ﬁrst generated
omized region with a central GA (antisense to the UC# of robust cleavage
ombinatorial guide sequence RNA library. Note that this guide sequence
sites, but there is no hhRz enzyme to promote cleavage of the target RNA.
eal. Guide RNAs bound to the target RNA are isolated by puriﬁcation of
rate the single stranded cDNA and then PCR is conducted to recover and
f annealing to target RNA. Using lower levels of target RNA the enriched
ated several times, with lower levels of target RNA to increase stringency.
regions of the target RNA that also contain NUC# cleavage sites.
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kiel, & Patzel, 2000; Zuker, 2003). It has become clear to us
that the optimum way to employ computational tools is to
use them in aggregate so that multiple parameters can be
used to estimate both steric and energetic features of local
RNA folding. We use a set of algorithms (MFold, SFold
and OligoWalk) to predict accessible sites in RNAs (Mak-
soud & Sullivan, 2003; Maksoud, Zuker, & Sullivan, sub-
mitted for publication; Sullivan & Taggart, 2007; Sullivan
et al., in preparation). We use MFold to obtain a rigorous
statistical analysis of the probabilities of sterically accessi-
ble regions in the fold. We test these outcomes with SFold
which uses an independent algorithm not dependent upon
free energy (DG) minimization to determine access proba-
bilities. Finally we use OligoWalk to measure and map
the local free energy (LFE) along the target RNA. We con-
volve all parameters and rank order the predicted accessible
regions. We call this approach multiparameter prediction of
RNA accessibility (mppRNA). mppRNA was successfully
applied to two mRNA targets coding for human rod opsin
and human secreted alkaline phosphatase (SEAP) (Sullivan
& Taggart, 2007; Sullivan, Yau, Taggart, & Maksoud, in
preparation). We are working to develop our convolution
model to predict suitable hhRz cleavage sites by validation
testing against eﬃcacy datasets from other targets.
Recent eﬀorts seek to identify HTS experimental sys-
tems to search for accessible sites in RNAs. mRNA Acces-
sible Site Tagging (MAST) is another HTS approach to
screen mRNAs for accessibility (Zhang et al., 2003). This
involves a combinatorial library of AS sequences bounded
by constant sequences used both to bind clamping oligonu-
cleotides (ODNs) and for PCR ampliﬁcation. With the
clamping ODNs only the combinatorial (random) region
is single stranded and available to anneal to target RNA.
Such a MAST ODN library is bound to an RNA target
that is ﬁxed to a magnetic bead. Unbound ODNs are
washed away and the bound tags ampliﬁed by PCR for
cloning and sequencing. The approach has a distinct limi-
tation in that annealing and washing temperatures are
physiological, which limits stringency and speciﬁcity.
Annealing sites of only 6–8 nt are identiﬁed whereas the
combinatorial library has randomized regions of 18 nt.
We were unsuccessful in applying the combinatorial MAST
approach to screen for accessible sites in human rod opsin
mRNA. However, we utilized our experience to develop
gene-speciﬁc MAST (gsMAST) to test accessibility at sites
in opsin mRNA predicted by mppRNA or previously
tested in cultured cells (Maksoud et al., submitted for pub-
lication) to validate this approach. gsMAST strongly con-
ﬁrmed accessibility at one of two sites where leads were
identiﬁed in our ﬁrst study (Maksoud et al., submitted
for publication) (Fig. 3). gsMAST also conﬁrmed accessi-
bility at most sites that were predicted by the in silico
mppRNA approach (Sullivan & Taggart, 2007; Taggart
& Sullivan, in preparation).
Allawi, Dong, Ip, Neri, and Lyamichev (2001) described
a combinatorial approach to determine accessible sites infour mRNA targets for AS and RNAi attack with random-
ized libraries attached to a constant upstream PCR
sequence that prime ﬁrst strand cDNA synthesis. We
recently developed a combinatorial approach also based
upon ﬁrst strand cDNA synthesis, which maps hhRz cleav-
age sites in regions of accessibility in any RNA. We call this
approach cDNA Mapping of Accessible Ribozyme Sites
(cMARS). The method is fast, simple, gel-based and quan-
titative. cMARS has validated sites of accessibility pre-
dicted by mppRNA and conﬁrmed by gsMAST (Sullivan
& Taggart, 2007; Taggart & Sullivan, in preparation)
(Fig. 4). The existing cMARS combinatorial library can
be used for HTS screening of accessibility in arbitrary
mRNA targets.
The biological nature of the target used to identify
accessible sites could have a substantial impact on PTGS
outcomes determined. We used in silico RNA targets,
in vitro transcribed naked cRNA targets, and mRNA tar-
gets transcribed in cellulo to measure accessibility. The ﬁrst
two deal with a simulated or real naked RNA, while the
latter is the form in which one expects the mRNA to be
made in vivo. Another form of target that we have not used
is an in vitro transcribed cRNA that is mixed with cellular
protein extract. This latter approach adds the variables of
protein RNA interaction and dynamics to screening for
accessible regions. Scherr and Rossi (1998) and Scherr
et al. (2000) used the latter approach to screen for accessi-
ble sites for AS molecules. Pre-mRNAs are bound by het-
erogeneous nuclear proteins during synthesis. There is
change in the composition of bound proteins upon pre-
mRNA splicing to form a mature mRNA, during transport
to the cytoplasm, and upon taking residence in the cyto-
plasm. Some of these proteins have structural or functional
roles and some are chaperones. The extent to which the
naked target cRNA is represented in the ﬁnal set of mRNA
structures or a singular native structure that become targets
for PTGS is not known (Woodson, 2000). Our in silico
approaches (mppRNA) identify high stability local second-
ary structures with large single stranded annealing plat-
forms. Strong local RNA secondary structures form
rapidly during transcription and are less likely to be
impacted by heterogeneous or speciﬁc RNA binding pro-
teins than are less stable regions. Use of a diverse tool set
to identify PTGS targeting sites is robust, especially if posi-
tive correlation of outcomes exists among diﬀerent
approaches as we observe thus far.
3.3. Identifying lead PTGS candidates
The next major bottleneck in PTGS development is test-
ing of many agents to identify lead candidates. PTGS
cDNAs are prepared from synthetic ODNs prior to cloning
in expression vectors (for Rz or RNAi). Ideally, one uses
an expression vector that optimizes eﬃcient cloning of
small PTGS cDNAs. One must give strong consideration
to the strength of promoter used to express both the PTGS
ligand and the target RNA. These choices will have pro-
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Anneal Mixture of Tags
Transcribe cRNA c UTP-Bio
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b
Fig. 3. Gene-speciﬁc mRNA accessibility site tagging (gsMAST). (a) Schematic. cRNA is transcribed in vitro with biotin-UTP and attached to magnetic
beads. A gsMAST probe is a clamped ODN that contain a single stranded antisense region of 18 nt (N18) that is directly complementary to a region of the
target mRNA, and upstream and downstream constant regions that are clamped by small complementary ODNs. A set of such probes complementary to
diﬀerent regions in a target are synthesized and annealed. The mixture is then allowed to anneal to the target under competitive conditions. The target and
beads are extensively washed. The annealed gsMAST tags are then displaced and ampliﬁed by PCR before cloning to obtain their sequence. The relative
number of clones isolated indicates the relative probability of access of that region. (b) Table of gsMAST tag screen of full-length human rod opsin
mRNA. All antisense tags were designed against human opsin mRNA based upon a prior hhRz study (Maksoud et al., submitted for publication). A
control tag was designed as a sense tag to opsin. The antisense tags were present at 2.5 lM while the control tag was present at 5.0 lM. The numbers of
tags of each type identiﬁed in two sequencing samples is shown. In one sample a single stranded deoxyribonuclease (Surveyor) was used to attempt a
decrease of background noise, while the other simple contained no nuclease (results were comparable). The expected outcome for uniform random
selection of outcomes is 4.125 for the sample without Surveyor and 4.0 for the sample with the nuclease. Chi-squared statistics were used to evaluate the
outcomes of the sampling compared to the expected frequency, without or with the nuclease (without nuclease: v2 = 183.0, critical value 12.59 (a = 0.05)
with degrees of freedom = 6, p < 0.001; with nuclease: v2 = 118.53, critical value 12.59 (a = 0.05) with 6 degrees of freedom, p < 0.001). For the sample
without the nuclease subset v2 analysis showed that the nonuniformity of the sample resides in L57-3 and UT1180 (v2 = 174.75, critical value 5.991
(a = 0.05), p < 0.001). For the sample with the nuclease subset v2 analysis showed that the nonuniformity of the sample resides in L57-3, L57-1 and
UT1180 (v2 = 92.72, critical value 7.815 (a = 0.05), p < 0.001). The most frequent binding gsMAST tag antisense sequence is L57-3 (5 0
GGTGACGTAGAGCGTGAG 3 0), which binds the sense sequence of opsin mRNA 5 0 CUCACGCUCUACGUCACC (264–281). The L57-1 antisense
sequence (5 0 GTAGAGCGTGAGGAAGTT 3 0) binds the overlapping (to L57-3) sense sequence of opsin mRNA 5 0 AACUUCCUCACGCUCUAC 3 0
(258–275). The 3 0UT1180 antisense sequence (5 0 TGGCTGGGGGAAGGTGTA 3 0) binds to the 3 0UT region of opsin mRNA 5 0 UACACCUUCCCCC
AGCCA 3 0 (1189–1206). The regions around 250 (33 nt, dominant substate) and 1180 (39 nt, co-dominant substate with 12 nt loop substate) have the
largest predicted single-stranded annealing sites in the target. A lead hhRz candidate targets the 250 region loop, whereas knockdown in the 1180 loop
occurs to a lesser level. The UT1411 site has a smaller predicted loop (14 nt) and supported lead hhRz identiﬁcation. The V230-1 site has only an 8 nt loop
that permits no hhRz knockdown.
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promoters have diﬀerent strengths of transcriptional initia-
tion by RNA polymerases type II or III. The concentration
of PTGS agent (the enzyme [E] (for Rz) or ligand [L] (for
AS and RNAi), [E] and [L] used synonymously hereafter)
and the target RNA (the substrate [S]) are dictated by
the relative promoter strengths and the natural decay rates
of the PTGS and target RNAs. Depending upon the pro-
moters and the half-lives of the PTGS and target RNA,
in the Michaelis–Menten enzymatic sense, the [S]/[E] ratio
can vary over many log orders in any given experimental
paradigm. If the PTGS promoter is not strong and its
RNA half-life short, it will be diﬃcult, if not impossible,
to measure target knockdown in any experimental para-
digm, even if the PTGS agent was able to recognize and
cleave the target with high eﬃciency. The useful dynamic
range in any PTGS agent screening experiment must be a
strongly speciﬁed variable. Once successful lead candidates
have been identiﬁed one can then explore the range of [S]/[E] ratios under which eﬃcacy remains manifest or is opti-
mized. We have used strong CMV and Pol-III promoters
to express hhRzs or shRNAs, and SV40 or CMV promot-
ers to express target mRNAs in cells.
To test discrete PTGS agents in cultured cells there are
several paradigms that might be used: (P1) co-transfection
of both target and PTGS expression plasmids into cells that
are naı¨ve to the expression of target and PTGS agent, (P2)
transfection of PTGS plasmid into a stable cell line that
expresses the target mRNA and protein, (P3) transfection
of PTGS plasmid into a stable cell line where target cDNA
expression is under tight experimental inducible control,
and (P4) evaluating eﬃcacy when both the target and the
PTGS agent are under inducible control in a stable cell line.
While P1 is the simplest paradigm, experimental variability
for two independent parameters adds to the number of
experiments necessary for strong statistical testing power
at chosen level of signiﬁcance. P2 has the advantage that
only a single PTGS plasmid is transfected, but the disad-
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Fig. 4. cDNA Mapping of Accessible Ribozyme Sites (cMARS). (a) Schematic. Numerous full-length target mRNAs are present in solution. cMARS
combinatorial libraries containing a constant 5 0 region (for downstream PCR primer binding) is followed by a random hexamer to probe accessible
regions, and followed by the antisense to NUH# (#DAN) (where D (complement to H) = G, U, A). A single site is accessible and elements of the library
able to anneal do so and saturate the site because the probes are in excess. cDNA synthesis from such primed sites allows PCR from any of a number of
upstream probe priming sites. The size of the gel band localizes the site of annealing and the nature of D and N in each library identiﬁes the precise hhRz
site in that region. (b) Shows an agarose gel with intense bands present between 200 and 300 base pairs. G, A, T, C lanes refer to the identity of the 3 0
terminal nt (N) of the hhRz (NUH#) antisense motif sequence 5 0 DAN 3 0. The size of the intense bands maps them (with a single forward PCR primer) to
the region around 250 nt. The two intense bands in the G lane correspond to CUH# cleavage motifs, the two intense bands in the A lane correspond to
UUH# cleavage motifs, the two intense bands in the T lane correspond to AUH#motifs, and the fainter bands in the C lane correspond to GUH# cleavage
motifs. There are a number of NUH# sites corresponding to these possibilities in the region. Absolute identity of the site is obtained by sequencing gel
puriﬁed bands.
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protein are already expressed and accumulated and cannot
be attacked by the PTGS agent transcribed by the transfec-
ted plasmid (ﬂoor knockdown eﬀect). This reduces
dynamic range of the assay. A good example of this
approach is the delivery of PTGS agents intended to
knockdown rod opsin levels in vivo. Rhodopsin is a highlystable protein at physiological temperatures and is stable
for at least 14 days in the mammalian eye. Knockdown
experiments in cell culture have a practical limit of 48–
72 h before cells overgrow. One expects that the lifetime
of opsin protein would far exceed the time limit of the
experiment, as was previously suggested in 293S cell culture
(Sung et al., 1991). All of the opsin protein already synthe-
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and translated at the time of PTGS plasmid transfection
is not subjected to PTGS agent knockdown. A 100%
knockdown of target mRNA within 24 h of transfection
(unlikely) will leave at least 50% opsin protein at assay
point at 48–72 h. P2 is a low dynamic range assay unless
the measured target protein has a relatively short half-life.
Targets with extremely short mRNA half-lives (minutes)
have intrinsic decay kinetics that are likely too fast for
the kinetic realm of PTGS agents. P3 is a more ideal strat-
egy but requires that stable low-oﬀ state robust-inducible
cell lines be generated to control a wide dynamic range of
target gene expression after the PTGS agent has been
transfected. An added feature of the P3 paradigm is that
the [S]/[E] ratio can be varied. [S]/[E] is expected to have
a substantial impact on PTGS eﬃcacy. In the P4 paradigm
both the target and the PTGS agent are induced to express
with diﬀerent inducers (e.g. doxycycline, IPTG). While two
gene regulated cell lines are considerably harder to realize,
this formulation adds ﬂexibility compared to P3 in that
much wider range of [S]/[E] ratios are achievable.
There may be question about the validity of culture sys-
tems to test PTGS agents to identify lead candidates. PTGS
occurs within the housekeeping metabolism of mammalian
cell biology. Transcription, RNA folding, intracellular
RNA traﬃcking, RNA-mediated catalysis, and ribosomal
translation are expected to occur by the same mechanisms,
with the same macromolecules, and on the same time scales
as they would otherwise occur in the cellular target system
in vivo. Therefore, eﬃcacy outcomes of PTGS testing in cell
culture expression systems are expected to be predictive of
in vivo performance, especially if the tested [S]/[E] range
simulates the realizable in vivo condition.
In the initial phases of lead candidate identiﬁcation we
recommend use of the P1 paradigm of cotransfection of
both ligand and target plasmids, with appropriate transfec-
tion eﬃciency controls (e.g. pEGFP-N1). We chose a high
ligand/target plasmid ratio when the ligand was expressed
by an intragenic adenoviral VAI promoter (Pol-III) and
the target was expressed by a CMV promoter (Pol-II).
Under this P1 condition one expects that the PTGS ligand
will be in substantial molar excess over target mRNA and
co-localized with target RNA in the cytoplasmic compart-
ment. Both conditions act to optimize annealing. The
expected outcome is a bias in the [E]/[S] ratio with the
PTGS agent in substantial excess over target (substrate).
Under these lead screening conditions [E] >> [S] and with
compartmental co-localization we expect that target acces-
sibility in live cells becomes the dominant factor in testing
for knockdown eﬃcacy.
We initially recommend screening for lead PTGS candi-
dates by the most eﬃcient and reliable approach to mea-
sure either the target RNA or/and protein. Measures of
target protein are the most eﬃcient means to quantitate
the relative knockdown of a series of PTGS agents, pro-
vided that one has a high aﬃnity monoclonal or polyclonal
antibody to use for protein detection. We initiallyemployed western analysis to quantitate target opsin pro-
teins co-expressed in HEK293E cells with a panel of
VA1-hhRzs under paradigm P1 (Maksoud & Sullivan,
2003; Maksoud et al., submitted for publication). With
such an approach we identiﬁed two lead hhRz candidates
against human rod opsin. However, we recognized a
profound bottleneck in screening for lead candidates with
western analysis, which is at best semi-quantitative, user-
dependent, slow and experimentally cumbersome. We then
invested substantial eﬀort to develop alternative high
throughput screening to measure target protein or RNA.
To relieve bottlenecks in screeningwe considered proteins
that are assayed easily by HTS plate readers. We considered
SEAPandvarious short half-life formsofEGFP (d2, d4) and
decided to develop the SEAP approach because cells secrete
the bulk of protein (95%) into the culture medium in propor-
tion to steady-state mRNA levels (Berger, Hauber, Hauber,
Geiger, &Cullen, 1988). This allows for live cell kinetic anal-
yses. Fusion RNAs are useful tools for HTS of gene expres-
sion (Hu¨sken et al., 2003). One can engineer a fusion RNA
between a target of interest and an easily assayed target such
as SEAPorEGFP.RNA folding is known to occur co-trans-
criptionally and weaker tertiary RNA structure forms sec-
ondary to stronger secondary structure (Tinoco &
Bustamante, 1999). Therefore, it is prudent to place the tar-
get upstream of the reporter in the fusion RNA. In this posi-
tion the reporter RNA component is less likely to impact the
folding of the target RNA component. To embrace the 3 0UT
of the target as a suitable PTGS attack site, it would be nec-
essary to convert all in-frame stop codons in the 3 0UT to cod-
ing triplets before in-frame fusion of the reporter cDNA.Or,
one can place the full-length unaltered target cDNA
upstream of an internal ribosome entry site (IRES) element
and the reporter cDNA downstream to form a bicistronic
mRNA that codes for both the target protein and the repor-
ter protein. With such a construct all four paradigms could
be used to screen panels of PTGS agents. PTGS agents direc-
ted to anneal to target RNA components will promote sup-
pression of the reporter protein fraction, which is readily and
reliably assayed in a 96-well plate reader type format, and the
target protein. ThisHTS approach has substantially relieved
bottlenecks to identify and optimize lead candidate PTGS
agents. TwohhRzs targeting regions of human opsinmRNA
predicted by SFold to have substantial accessibility (CUA#
332, AUC# 1058) were compared for eﬃcacy compared to
control vector without hhRz cDNA in a stable cell line
expressingRho-IRES-SEAP (Fig. 5). Statistically signiﬁcant
KD is found for the hhRz predicted to have higher probabil-
ity access.We recently used thisHTSplatform to identify ﬁve
lead candidate hhRzs against human rodopsinmRNA(Kol-
niak, Yau, Taggart, & Sullivan, 2007; Yau & Sullivan, 2007,
submitted for publication).
3.4. Optimizing lead candidates
Lead PTGS candidates will likely need to be optimized,
and certainly characterized under a broad range of [S]/[E]
Fig. 5. HTS hhRz screening. A dicistronic expression construct with built with full-length human Rho cDNA (transcription start to immediately before
ﬁrst (dominant) polyA signal), followed by an encephalomyocarditis virus internal ribosome entry site element, followed by the cDNA for engineered
human secreted alkaline phosphatase, and then a polyA signal. This construct was expressed stably in HEK293S cells. Cells were transfected with the
pUC-VAI vector without hhRz cDNA (control) or with hhRz cDNAs coding for hhRzs that target NUH# sites at 332 and 1058 in human RHO.
Extracellular SEAP was assayed 48 h later using a HTS ﬂuorescence microplate reader. (a) Two regions targeted in opsin mRNA by SFold. The blue box
indicates the expected span of annealing of a 7 nt/7 nt hhRz to the target. The 15 nt regions (blue boxes) embracing the 332 CUA# and 1058 AUC#
cleavage sites have similar mean accessible probabilities (0.592 ± 0.095, 0.659 ± 0.081, respectively) as determined by SFold (not statistically diﬀerent,
p = 0.596). (b) The mean levels of SEAP at 48 h post-transfection for control (pUC-VAI), pUC-VAI-hhRz-332, or pUC-VAI-hhRz-1058. One-way
ANOVA demonstrated that the means were signiﬁcantly diﬀerent (p = 2.53 · 106). Post-hoc t-tests shows that there was no signiﬁcant diﬀerence between
control and hhRz-332 (p = 0.896) and signiﬁcant diﬀerences between control and hhRz-1058 (p = 2.82 · 107) and between hhRz-332 and hhRz-1058
(p = 3.19 · 104). (For interpretation of the references in color in this ﬁgure legend, the reader is referred to the web version of this article.)
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varying the length of the complementary region. shRNA
probes will be cut by Dicer to 21 nt double stranded ele-
ments, so the only modulation possible is to create mis-
matches between the RNAi and the target over the
region of annealing or, if synthetic siRNA is used, to
use nucleotide analogues that aﬀect binding aﬃnity. This
may or may not inﬂuence the leaving rate of cleavage
product by Ago2 in RISC, because the latter ATP hydro-
lysis energy to aid product release (Haley & Zamore,
2004). Optimization potential is, however, very strong
for Rzs. A ﬁrst critical test for a lead hhRz will be to
compare target knockdown by lead agents with catalytic
core mutants of each of the same. Ideally, catalytic coremutations lead to complete reversal of knockdown, which
indicates that the eﬀect is purely catalytic in nature. More
likely, there will be a fraction of knockdown that persists
despite catalytic inactivation. This component represents
an antisense eﬀect, which is directly related to the binding
energy of the hhRz AS ﬂanks. It is possible to optimize
the hhRz AS ﬂanks with a kinetic model (Stage-Zimmer-
mann & Uhlenbeck, 1998). In this model the AS ﬂank
lengths or composition (mismatches) can be optimized
in order to maximize speciﬁcity while avoiding cleavage
product inhibition (Bertrand, Pictet, & Grange, 1994;
Herschlag, 1991).
Optimizing lead candidates required identiﬁcation of the
best enzymatic form of the hhRz. It is possible to formulate
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II and its capping sequence, core nucleotides that aﬀect
catalysis, or the addition of tertiary accessory elements that
are now known to aﬀect catalytic performance (e.g. Khvor-
ova, Lescoute, Westhof, & Jayasena, 2003). Such modiﬁca-
tions are independent of the AS ﬂank binding energy which
is well characterized by the hhRz kinetic model. Instead,
such modiﬁcations modulate hhRz catalytic rate and
potentially the religation rate, which must remain low.
For example, minimization of Stem II to two base pairs
has been shown to speed up hhRz catalysis while expan-
sions beyond 6 bp have been shown to inhibit catalysis
(Persson, Hartmann, & Eckstein, 2002). Such rationale
modiﬁcations of the hhRz can be tested against any suit-
able target (e.g. SEAP), and are expected to translate
equivalently well to hhRzs directed to any such target.
We used our HTS SEAP platform to rapidly identify the
best hhRz form in a chimeric RNA (Yau & Sullivan,
2007, submitted for publication). We evaluated at least
10 times as many hhRz candidates in less than one half
of the time when compared to classical western analysis.
Screening will occur much faster with robotic tools on
the platform.
Another concern for optimization of a lead candidate
PTGS agent is that it is active against the native RNA that
will exist in vivo. Use of fusion or bicistronic mRNAs in
HTS identiﬁcation of leads has a small but ﬁnite potential
for the accessory RNA elements (e.g. the reporter element)
to inﬂuence the folding of the true target RNA component,
and thus impact PTGS knockdown. In the worst case sce-
nario accessory elements could promote exposure of single
stranded annealing platforms that are not present in the
native mRNA, or promote closure of a truly accessible
site(s) that would remain unidentiﬁed. A successful hhRz
under such a HTS screen could ﬂop in a native target assay
or in vivo proof-of-principle test. In the best case scenario
there is no inﬂuence of accessory or reporter elements on
the folding of the native target RNA and the PTGS agent
is expected to have equivalent performance in HTS assays
and in vivo. Clearly, the outcomes could test between the
extremes. This puts the experimenter back into the discour-
aging boat of having to conduct low throughput assays.
We used our expertise in modern electro-optics (Sullivan,
1998) to develop a quantitative HTS platform to measure
any native target protein (and possibly its mRNA). From
research into the spectral range of cellular autoﬂuorescence
we developed a microscope-based imaging platform that
measures and reliably quantiﬁes native proteins (and we
expect RNAs) normalized to both cell number and trans-
fection eﬃciency in single wells of a 96-well array. A high
aﬃnity IgG antibody is needed and is usually available
for disease target proteins. The antibody (or ODN) is ﬁrst
labeled with a high quantum eﬃciency, photostable, far-red
ﬂuor and binds to expressed target protein (or mRNA) in
cells grown, transfected, ﬁxed and permeabilized in a 96-
well format (Butler, Kolniak, & Sullivan, 2007; Butler,
Kolniak, Yau, Sullivan, in preparation) (Fig. 6). ThisHTS platform for native target protein relieves a major
bottleneck in PTGS development and optimization.
Robotic enhancements will speed analysis on this platform.
Given appropriate antibodies, ODNs and ﬂuors, we expect
that this system will be useful for high content screening
(e.g. multiple simultaneous target quantitation).
With these tools in hand we now expect to rapidly screen
for accessibility sites, identify lead hhRz and shRNA can-
didates, and optimize these for preclinical performance.
We can do this for arbitrary molecular disease targets at
this time. This platform will be of substantial use for bring-
ing HTS screening for PTGS agent development into the
academic sector. This platform might be of interest to those
planning development of PTGS agents against targets of
ocular interest.
Finally, the optimized lead candidate should be tested in
human or mammalian cultured cells to simulate the widest
range of possible in vivo conditions. PTGS agent outcomes
in human cultured cells are expected to simulate perfor-
mance in vivo provided that the same ligand [E]/target [S]
ratios are achieved. The levels of target mRNA and protein
and the level of PTGS agent itself should be quantitated
under a range of [E]/[S] ratios. The kinetics of knockdown
of target mRNA and protein by the PTGS agent, and their
intrinsic rates of degradation in the absence of PTGS
agents should be measured. The cellular lifetime of the
PTGS agent should also be measured. Outcomes in cells
can then be compared to outcomes in vivo where the same
levels should be quantiﬁed. With such robust quantitation
the gene therapeutic outcomes and kinetics could be quan-
titatively modeled. We strongly advise use of inducible sta-
ble expression lines for the target and possibly the PTGS
ligand (paradigms P3, P4). Maintaining cultured cells for
substantial periods of time will promote progressive loss
of unselected episomal plasmids and hence nonstationarity
in the [L]/[S] ratios.
Finally, if there are several leads it is reasonable to test
for additive and synergistic eﬀects on target knockdown
especially if well separated annealing sites are targeted.
This is managed by P1 paradigm co-transfections. It is also
feasible to examine a combined strategy of knockdown and
reconstitution with an allelic variant WT expression con-
struct in cultured cell systems, albeit with some caveats.
One can separately compare the KD capacity of a hhRz
or RNAi against WT and mutant targets, and the expres-
sion of an engineered resistant allelic variant WT RNA.
It is more diﬃcult to achieve this when WT, mutant and
allelic variant-WT (engineered mRNA coding for WT pro-
tein that cannot be degraded by PTGS agent) constructs
are expressed in the same cultured cells (Cashman et al.,
2005).
3.5. Preclinical testing of lead candidate PTGS agents
Ultimately the choice of a preclinical animal model is
paramount to reliably predict outcomes of a human clinical
trial. There are two levels of approach in preclinical testing.
Fig. 6. Quantitative immunocytochemistry system. (a) HEK293S cells (no opsin) and WT-HEK293S cells (expressing 3 million copies of human opsin per
cell) were ﬁxed and permeabilized in 96-well dishes. Permeabilized cells were then exposed to an Alexa-647-labelled 1D4 mouse monoclonal IgG antibody
and washed. Cells were imaged on an automated stage-controlled inverted ﬂuorescence microscope imaging system equipped with a Hg-vapor lamp and an
Alexa-647 speciﬁc dichroic cube and a high numerical aperture 20· lens. Cells were also exposed to SYTOXGreen which binds avidly to nuclear DNA and
can be used to count nuclei. 293S cells demonstrate only dim background non-speciﬁc and uniform staining with 1D4-Alexa-647, whereas WT-HEK293S
cells have intense staining. SYTOX Green labelsnuclei in both lines and is used to normalize protein measures in each well to cell number. (b) Mean Alexa-
647 ﬂuorescence counts in 293S cells and WT-293S cells (±SEM). Note that the abscissa has a negative extent to demonstrate the small number of counts
in the 293S category. By parametric t-test the means were signiﬁcantly diﬀerent (p = 2.6 · 106). Dynamic range is over 1000 in this experiment.
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mammalian model (generally small, e.g. mice, rats) which
has a phenotype based upon expression of the target of
interest, even though that mRNA target is generally not
expressed from a human gene. There are many mouse
transgenic models that have been engineered to express
rod opsin mutant mRNAs (e.g. Li, Snyder, Olsson, & Dry-
ja, 1996; Naash, Hollyﬁeld, Al-Ubaidi, & Baehr, 1993; Ols-
son et al., 1992). Large scale pig transgenic (P347S, P347L
rod opsin) and a naturally occurring dog (T4R rod opsin)
models of RP also exist. However, when PTGS agents aredeveloped to target non-human homologue mRNAs they
may later be unable to target a human mRNA. Even in
genes coding for highly conserved proteins (e.g. rod opsins)
the 5 0UT and 3 0UT components of the mRNA are diver-
gent and the coding region is likely to contain amino acid
variations or third position codon wobble variations
(degeneracy). A PTGS agent designed to target (anneal
to) a particular region of the primary sequence in an animal
RNA may succeed in proof-of-principle, but may encoun-
ter substantially divergent sequence in the human mRNA,
and thus be clinically useless. Or, the targeted region could
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human mRNA this particular region may not be accessible
and the costly investment in PTGS development is lost.
Fortunately, homology of target primary sequences across
species can be checked prior to PTGS development in order
to allow testing of the same agents in both small and large
scale mammalian models and in human trials. A more sub-
tle issue is that the structure of the animal mRNA, which is
the primary barrier to successful annealing, is likely to be
substantially diﬀerent from human, even when the proteins
coded are highly conserved. We tested this hypothesis
through in silico folding of full-length rod opsin mRNAs
from four animals: human, mouse, pig and dog (Fig. 7).
Only the coding region was folded computationally to
avoid the additional complexity of 5 0UT and 3 0UT regions,
which are known to be divergent. These mRNA segments
of identical length code for highly conserved proteins
(e.g. there are only 18 out of 348 amino acids that are dif-
ferent between mouse and human). It is clear that the MFE
folding structure of the coding regions is markedly diﬀerent
across species. The 5 0UT and 3 0UT segments would addFig. 7. RNA folding of the homologous coding regions of opsin mRNAs. T
mouse (Accession No. NM 145383), dog (Accession No. X71380) and pig (Acc
MFold at 37 C. Regions folded were: 96–1142 (human), 79–1125 (mouse), 137
through the stop codon. The MFE state is shown for each opsin homologue.structural complexity. Therefore, even if the PTGS ligand
developed for the animal mRNA has high homology to a
region of the human mRNA target, this is no guarantee
that the local secondary structure and accessibility will be
similar between the human and animal targets. Compari-
son of sequence homology between human and animal tar-
gets at the primary sequence level is insuﬃcient as a reliable
predictor. At a minimum a secondary structural analysis
could be conducted in silico to compare the RNA folding
conformational landscape and target site accessibility at
increasingly wider folding windows embracing the central
region of intended annealing. However, a human mRNA
is the ideal target to begin PTGS development. PTGS
development can be managed in cost-eﬀective cell culture
systems that express true full-length mutant and/or WT
human mRNAs and simple assays of mRNA/protein per-
formed to measure eﬃcacy. To consolidate the timeline
and cost of PTGS development for human therapies, we
propose that preclinical testing be conducted in mouse
models that express human transgenes on a homozygous
knockout background of the mouse homologue. It is rea-he 1047 nt long coding regions of human (Accession No. NM 000539.2),
ession No. AF008947) rod opsin mRNAs were folded independently using
–1183 (dog) and 1–1047 (pig). These regions all span from the start codon
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mRNA in mouse or human photoreceptors or in other ret-
inal cell types (e.g. RPE). There are mouse models that
express human opsin mRNAs on the mouse rod opsin
knockout background (Li et al., 1996; McNally et al.,
1999). To our knowledge mouse models of human mutant
and human WT transgenes on a mouse homologue knock-
out background are nonexistent for other disease genes at
this time. This stands as a call to interest and funding for
the development of such models.
Another issue that was recently addressed (Cashman
et al., 2005) is the extent to which the plethora of single
nucleotide (nt) mutations that promote human hereditary
retinal and macular degenerations might promote changes
in the structure of mRNA targets that could inﬂuence
PTGS eﬃcacy. We tested this hypothesis in silico. We used
the full-length dominantly transcribed human rod opsin
transcript (1–1532) and made the following single nt muta-Fig. 8. Eﬀect of single nucleotide mutations on human rod opsin mRNA foldin
there are current animal models and compared the folding relative to WT hum
were made in the in silico target (1–1532 nt by NM 000539.2). The ﬁrst 1400 nt
apparent diﬀerences in the secondary structures of these minimal folding ene
shown. Note the large single stranded loop in WT and all mutant RNAs whic
target for hhRz and RNAi knockdown.tions for which there are (at least) murine models of dis-
ease: T17M, P23H, G90D, K296E and P347S. WT
mRNA was used as control. All mRNAs were folded using
MFold and the structure of the MFE state was compared.
All of the mutant mRNAs had the same global mRNA
structure relative to WT mRNA folded under identical
conditions (Fig. 8) (T17M and G90D not shown). Single
nt mutations do not cause global changes in mRNA struc-
ture at least for this model target mRNA. Such hypotheses
would be impossible to test with contemporary experimen-
tal tools.
Preclinical testing is the single remaining technological
bottleneck in PTGS development. There are several proce-
dures during PTGS testing that might have room for opti-
mization. These include animal injections, psychophysical
testing (when used), ERG testing, and histology. Highly
eﬃcient organizational schemes may be the best bottleneck
relief that is possible. Substantial improvement might beg. We generated and folded in silico ﬁve human opsin mutations for which
an opsin. P23H, K296E and P347S are shown relative to WT. Mutations
(MFold limit) of each RNA was folded with MFold at 37 C. There are no
rgy states, and two additional mutants (T17M and G90D) which are not
h is found by MFold in the MFE. This region has proven to be a suitable
J.M. Sullivan et al. / Vision Research 48 (2008) 453–469 467made by conducting subretinal injections such that the
entire retina enters into shallow detachment and nearly
all photoreceptors or RPE are transduced by the vector.
This would reduce diﬃculties in eﬃcacy evaluations due
to loss of dynamic measurement range when only a fraction
of the retina is transduced, yet the total retina or RPE mass
contributes to ERG measures or molecular measures of
target RNA or protein. Measure of transfection eﬃciency
in each eye for quantitative normalizations can be reliably
obtained with co-expression of a ﬂuorescent protein (e.g.
EGFP). Recent studies have employed rodent retinal
explants as a tool for initial testing of PTGS agents (Kiang
et al., 2005). This approach has substantial potential for
higher throughput testing. Finally, recent eﬀorts suggest
that ERG measurements in mice could be conducted at
higher levels of throughput (Dalke et al., 2004). It appears
that substantial technological development could be direc-
ted to relieve bottlenecks in the ﬁnal remaining area of pre-
clinical testing.
4. Conclusions
The contemporary development of a successful PTGS
therapeutic remains a diﬃcult task well described by the
term biocomplexity. We presented an overview of PTGS
technologies. We presented emerging technologies used in
this and other labs to reduce bottlenecks in development
of PTGS agents for gene therapy. We expect that these
tools will be useful for development of PTGS agents
against other validated molecular targets in retinal, macu-
lar and ocular diseases, or in general medicine. We pre-
sented a base of knowledge to begin work, and a sense of
the pitfalls. We want to encourage other investigators by
providing infrastructure to proceed down these investiga-
tive paths in the interests of the patients suﬀering with these
diseases. A rigorous review of strategies and variables in
PTGS agent development will be presented elsewhere (Sul-
livan et al., in preparation).
5. Methods
5.1. RNA secondary structure prediction
The secondary structure of mRNAs targets was determined with a free
energy minimization algorithm (MFold, version 2.3) (Zuker, 2003).
MFold was used at 37 C with 10 kcal/mol window, a maximum of 99
structures, and with a diﬀerence window of 3 bp.
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